Physician profile
Heather Pullen
NPI 1659987725
$4,969.32
in general payments reported to CMS, 2019-2025
32 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $397 · 2023: $550 · 2024: $1,605 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,986 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,986.21 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $641.82 | 2021-2025 | Sotyktu, Cobenfy |
| Janssen Biotech, INC. | $507.11 | 2023-2025 | Tremfya |
| Abbvie INC. | $472.78 | 2021-2025 | |
| Lilly USA, LLC | $305.72 | 2022-2025 | Taltz, Ebglyss, Zepbound |
| Paratek Pharmaceuticals, INC. | $245.78 | 2024-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals Lp | $232.87 | 2021-2025 | Airsupra |
| Davol INC. | $200.87 | 2022-2025 | |
| Galderma Laboratories, L.P. | $182.55 | 2024-2025 | Nemluvio |
| Novo Nordisk INC | $175.07 | 2022-2025 | Wegovy |
| Leo Pharma INC. | $167.96 | 2024-2025 | Adbry, Anzupgo |
| Amgen INC. | $166.02 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $147.16 | 2024-2025 | Bimzelx |
| Edwards Lifesciences Corporation | $139.78 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Dexcom, INC. | $135.62 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Vertex Pharmaceuticals Incorporated | $124.86 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $122.44 | 2024 | Valtoco |
| Novartis Pharmaceuticals Corporation | $115.68 | 2023-2025 | |
| Glaxosmithkline, LLC. | $108.85 | 2023 | Shingrix |
| Regeneron Healthcare Solutions, INC. | $105.79 | 2024-2025 | Libtayo, Dupixent |
| Sandoz INC. | $104.96 | 2023-2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.18 | 2022 | |
| Organon LLC | $76.06 | 2024-2025 | Hadlima, Vtama |
| Mylan Specialty L.P. | $75.93 | 2022-2023 | Yupelri |
| Boston Scientific Corporation | $65.47 | 2021 | |
| Dermavant Sciences, INC. | $54.99 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $47.28 | 2024-2025 | |
| Medtronic, INC. | $44.28 | 2025 | Inceptiv |
| Botanix Sb INC | $34.81 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $24.43 | 2025 | Zoryve |
| Genzyme Corporation | $18.58 | 2024 | |
| Genentech USA, INC. | $18.33 | 2024 | Erivedge |
| Verrica Pharmaceuticals INC. | $14.29 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Pullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.